← All trials
NCT02172872
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2014
- Primary completion
- Dec 1, 2019
- Completion date
- Dec 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- HagaZiekenhuisOverall official - principal investigator
- Radboud UniversityOverall official - principal investigator
- University of FreiburgStudy chair
- Gruppo Italiano Malattie EMatologiche dell'AdultoCollaborator
- Janssen Pharmaceutica NVCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.